These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37210896)

  • 21. Association of thrombocytopenia with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis based on the data from FDA adverse event reporting system database.
    Liu G; Zhang S; Mo Z; Huang T; Yu Q; Lu X; He P
    Front Pharmacol; 2024; 15():1407894. PubMed ID: 38953101
    [No Abstract]   [Full Text] [Related]  

  • 22. The association of hypophysitis with immune checkpoint inhibitors use: Gaining insight through the FDA pharmacovigilance database.
    Tang Q; Han Y; Song M; Peng J; Zhang M; Ren X; Sun H
    Medicine (Baltimore); 2024 Mar; 103(13):e37587. PubMed ID: 38552079
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety profile of immune checkpoint inhibitors: An analysis of the Italian spontaneous reporting system database.
    Cutroneo PM; Isgrò V; Ientile V; Santarpia M; Ferlazzo G; Fontana A; Carrega P; Matarangolo E; Barnaba S; Spina E; Trifirò G
    Br J Clin Pharmacol; 2021 Feb; 87(2):527-541. PubMed ID: 32495965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gastrointestinal adverse events associated with immune checkpoint inhibitors: a pharmacovigilance analysis of the EudraVigilance and VigiAccess databases.
    Rabbani SA; Khurana A; El-Tanani M; Arora MK; Sharma S; Sridhar SB; Dubey H
    Expert Opin Drug Saf; 2024 Oct; ():. PubMed ID: 39392233
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis on the risk of myasthenia gravis related to immune checkpoint inhibitors based on the US FDA Adverse Event Reporting System.
    Kong Q; Wang H; Ren X; Zhuo Y; Peng J
    Cancer Med; 2023 Oct; 12(19):19491-19499. PubMed ID: 37724594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System.
    Wang H; Yang H; Zhou X; Zhang X
    Clin Ther; 2023 Feb; 45(2):151-159. PubMed ID: 36682994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PD-1/PD-L1 inhibitor-induced immune thrombocytopenia: A pharmacovigilance study and systematic review.
    Moore DC; Elmes JB; Arnall JR; Strassel SA; Patel JN
    Int Immunopharmacol; 2024 Mar; 129():111606. PubMed ID: 38359661
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
    Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
    J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns.
    Gougis P; Hamy AS; Jochum F; Bihan K; Carbonnel M; Salem JE; Dumas E; Kabirian R; Grandal B; Barraud S; Coussy F; Hotton J; Savarino R; Marabelle A; Cadranel J; Spano JP; Laas E; Reyal F; Abbar B
    JAMA Netw Open; 2024 Apr; 7(4):e245625. PubMed ID: 38630478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
    Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
    J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulmonary Immune-Related Adverse Events of PD-1 Versus PD-L1 Checkpoint Inhibitors: A Retrospective Review of Pharmacovigilance.
    Ebinama U; Sheshadri A; Anand K; Swaminathan I
    J Immunother Precis Oncol; 2023 Nov; 6(4):177-184. PubMed ID: 38143955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study.
    Salem JE; Manouchehri A; Moey M; Lebrun-Vignes B; Bastarache L; Pariente A; Gobert A; Spano JP; Balko JM; Bonaca MP; Roden DM; Johnson DB; Moslehi JJ
    Lancet Oncol; 2018 Dec; 19(12):1579-1589. PubMed ID: 30442497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Occurrence of Encephalitis Due to Immune Checkpoint Inhibitors: A Pharmacovigilance Study.
    Chisaki Y; Hata H; Matsumura C; Yano Y
    Ther Innov Regul Sci; 2022 Mar; 56(2):323-332. PubMed ID: 35006589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: A real-world study of the FDA adverse event reporting system.
    Moore DC; Elmes JB; Arnall JR; Strassels SA; Patel JN
    Int Immunopharmacol; 2022 Sep; 110():109015. PubMed ID: 35803131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ocular adverse events with immune checkpoint inhibitors.
    Fang T; Maberley DA; Etminan M
    J Curr Ophthalmol; 2019 Sep; 31(3):319-322. PubMed ID: 31528768
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune-related adverse events and immune checkpoint inhibitors: a focus on neurotoxicity and clinical management.
    Ruggiero R; Di Napoli R; Balzano N; Ruggiero D; Riccardi C; Anatriello A; Cantone A; Sportiello L; Rossi F; Capuano A
    Expert Rev Clin Pharmacol; 2023 May; 16(5):423-434. PubMed ID: 37144360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database.
    Hasegawa S; Ikesue H; Nakao S; Shimada K; Mukai R; Tanaka M; Matsumoto K; Inoue M; Satake R; Yoshida Y; Goto F; Hashida T; Nakamura M
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1279-1294. PubMed ID: 32869941
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune Checkpoint Inhibitors and Venous Thromboembolism: An Analysis of the WHO Pharmacovigilance Database.
    Allouchery M; Beuvon C; Pérault-Pochat MC; Roblot P; Puyade M; Martin M
    Clin Pharmacol Ther; 2022 Jul; 112(1):164-170. PubMed ID: 35426120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuromuscular junction dysfunctions due to immune checkpoint inhibitors therapy: An analysis of FAERS data in the past 15 years.
    Zhang P; Lao D; Chen H; Zhao B; Du Q; Zhai Q; Ye X; Yu B
    Front Immunol; 2022; 13():778635. PubMed ID: 36081514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative efficacy and safety of immune checkpoint inhibitors for unresectable advanced melanoma: A systematic review and network meta-analysis.
    Li Y; Liang X; Li H; Chen X
    Int Immunopharmacol; 2023 Feb; 115():109657. PubMed ID: 36608446
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.